Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

information)(Unaudited)Three Months EndedNine Months EndedSeptember 30, September 30,2010200920102009Revenue:Product sales and royalties

$  7,230$
7,461$  21,968$  24,456License, collaboration and other

30,6952,76291,7578,466Total revenue

37,92510,223113,72532,922Operating costs and expenses:Cost of goods sold

6,2456,13415,43022,139Research and development

27,72423,03176,61070,396General and administrative

10,1819,91729,40130,024Total operating costs and expenses

44,15039,082121,441122,559Income (loss) from operations

(6,225)(28,859)(7,716)(89,637)Non-operating income (expense):Interest income

3695601,2253,160Interest expense

(2,826)(2,928)(8,686)(9,213)Other income, net

249120436368Total non-operating expense

(2,208)(2,248)(7,025)(5,685)Loss before provision (benefit) for income taxes

(8,433)(31,107)(14,741)(95,322)Provision (Benefit) for income taxes

278(140)617(479)Net loss

$ (8,711)$ (30,967)$ (15,358)$ (94,843)Basic and diluted net loss per share

$   (0.09)$
(0.33)$
(0.16)$
(1.02)Weighted average shares outstanding used incomputing basic and diluted net loss pershare

94,21392,78993,97292,621NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Nine Months Ended Sept 30,20102009Cash flows from operating activities:Net loss

$ (15,358)$   (94,843)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization

12,49911,076Stock-based compensation

12,7167,290Deferred rent

1,084-Other non-cash transactions

(1,260)(124)Changes in operating assets and liabilities:Accounts receivable

(752)4,505Inventory

(4,989)389Other assets

1(1,272)Accounts payable

1,755(4,047)Accrued compensation

500(1,859)Accrued expenses

4,090(4,610)Accrued clinical trial expenses


'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 16, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical ... CMED ), a leading China-based ... its unaudited financial results for the ... 2011 ("1Q FY2011") today.1 Q ...
... More than a decade of targeted Muscular Dystrophy Association-funded ... support of the MDA Labor Day Telethon and thousands ... providing financial assistance for the start of the first ... pharmacokinetics clinical trial of an exon-51 skipping drug, eteplirsen, ...
Cached Medicine Technology:China Medical Technologies Reports First Fiscal Quarter Financial Results 2China Medical Technologies Reports First Fiscal Quarter Financial Results 3China Medical Technologies Reports First Fiscal Quarter Financial Results 4China Medical Technologies Reports First Fiscal Quarter Financial Results 5China Medical Technologies Reports First Fiscal Quarter Financial Results 6China Medical Technologies Reports First Fiscal Quarter Financial Results 7China Medical Technologies Reports First Fiscal Quarter Financial Results 8China Medical Technologies Reports First Fiscal Quarter Financial Results 9China Medical Technologies Reports First Fiscal Quarter Financial Results 10China Medical Technologies Reports First Fiscal Quarter Financial Results 11China Medical Technologies Reports First Fiscal Quarter Financial Results 12China Medical Technologies Reports First Fiscal Quarter Financial Results 13China Medical Technologies Reports First Fiscal Quarter Financial Results 14China Medical Technologies Reports First Fiscal Quarter Financial Results 15China Medical Technologies Reports First Fiscal Quarter Financial Results 16China Medical Technologies Reports First Fiscal Quarter Financial Results 17China Medical Technologies Reports First Fiscal Quarter Financial Results 18China Medical Technologies Reports First Fiscal Quarter Financial Results 19MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy 2MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy 3MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy 4
(Date:4/23/2014)... Time Physical Activity on Mobility Limitation in Old Age ... risk of mobility limitation in old age, whereas leisure-time ... a study which followed up 5,200 public sector employees ... Gerontology Research Center in Finland and the Finnish Institute ... repetitive, wears the body and lasts for several hours ...
(Date:4/23/2014)... Methylphenidate, also known as Ritalin, may prevent the depletion ... Science , a journal of the Association for Psychological ... a diet or trying to focus attention on a ... suggests one potential explanation for this difficulty: Exerting self-control ... to exert self-control effectively on subsequent tasks. , "It ...
(Date:4/23/2014)... of Alzheimer,s disease has been a rapidly evolving ... the latest crook in the research road, scientists ... between proteins associated with the disease. The report, ... Neuroscience , could have important implications for developing ... and colleagues explain that for years, research has ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... Society of ... Surgeons Annual Meeting, BALTIMORE, Oct. 28 One facelift or ... In fact,plastic surgeons analyze facial features and configurations to,individualize results based ... at the American Society of Plastic Surgeons (ASPS) Plastic,Surgery 2007 conference ...
... Annual Meeting, BALTIMORE, Oct. 28 While the ... to for fear of sagging,breasts. However, breastfeeding alone has ... first-of-its-kind study presented today at the,American Society of Plastic ... women who come in for breast surgery tell us ...
... in which the bladder forms outside of the abdomen ... with the same condition, according to a small study ... The condition, known as bladder exstrophy, requires a series ... early adolescence.The findings are being reported at the American ...
... 2007 MedImmune, Inc. today announced it will present ... 2007 National Conference & Exhibition, adding to the companys ... syncytial virus (RSV), a leading cause of hospitalization among ... that provide key insights into how we can optimize ...
... connected, study finds , THURSDAY, Oct. 25 (HealthDay ... a follow-up osteoporosis management program that includes electronic ... , Osteoporosis -- which increases the risk of ... 65 and older. Medication can greatly reduce fracture ...
... American Red Cross,Blood Services national system continues to ship ... to help stabilize the blood,supply in the region affected ... provided nearly 2,000 blood products to date,in support of ... drives in southern California have been curtailed due to ...
Cached Medicine News:Health News:Facelift, Botox, or Both? Depends Upon Your Decade of Life 2Health News:Facelift, Botox, or Both? Depends Upon Your Decade of Life 3Health News:Breastfeeding Does Not Create Sagging Breasts; Study Throws Out Old Wives' Tale 2Health News:MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics 2Health News:Older Women Gain From Good Post-Fracture Care 2Health News:American Red Cross Blood Services Supports Blood Needs of Southern California 2
...
... System is your system. CONMED's family of ... specialty. New, state-of-the art generators feature proprietary ... a continuous synchronization of current and voltage ... architecture enables the system to sample current ...
... biologically based adhesive supplied as a ... of a liquid substrate and crosslinker ... bleeding. When combined the ... a prepared wound and tenaciously adhere ...
... DERMABOND* Topical Skin Adhesive gives you ... adhesive is intended for topical application only ... of wounds from surgical incisions, including punctures ... cleansed, trauma-induced lacerations. DERMABOND adhesive may be ...
Medicine Products: